Contamination Control Strategies Sterile and Non-Sterile Manufacturers
Robert L. Iser
As part of the planning committee, I’m very pleased to share this year’s theme for the 2018 ISPE Quality Manufacturing Conference, June 4-6 in Arlington, VA: Manufacturing and Quality: Present and Future Opportunities to Ensure Continuous Improvement; and we have put together three very interesting and timely tracks on Regulatory, Quality and Manufacturing, and Facilities and Equipment topics.
One session that I am very excited about is the one centered on Contamination Control Strategies. The session will include perspectives from experts in the pharma industry and the U.S. FDA; and will delve into Contamination Control Strategies for sterile and non-sterile manufacturers as an essential consideration for preventing product contamination. Pharma industry experts will share successful ways to communicate and manage contamination controls, with real-life examples.
Attendees will also have a chance to participate in a Q&A session that poses questions such as:
Do you have a dedicated Contamination Control lead or department?
What is the leading root cause for final product contamination at your company?
Do you have process risk assessments that include microbial ingress and contamination risks?
The ISPE Quality Manufacturing Conference is the foremost pharmaceutical quality event of the year. It provides a unique forum for attendees and speakers from industry, academia, and regulatory to address areas for opportunities to assure innovation and continuous supply of high-quality products to our patients.
Here’s what you can expect:
Dynamic keynote presentations featuring leaders from leading experts in FDA, MHRA, and Industry.
Content-rich sessions led by industry experts—introducing the latest in leading edge approaches in international regulatory convergence, quality and manufacturing potential, and facilities and equipment innovation
A featured session dedicated to the success of Women in Pharma®
Strong regulatory participation throughout the sessions, including FDA, MHRA (UK), and PMDA (Japan), culminating in a final interactive global regulatory forum where participants have the opportunity to ask questions directly to regulators.
Register by Monday, 26 March to take advantage of our lowest rates — saving you $400 or more!
A committee under the auspices of the National Academies of Sciences, Engineering, and Medicine (NASEM) is conducting a study with the aim of producing a consensus report that identifies emerging and upcoming technologies that have the potential to...
In response to the COVID-19 pandemic, several governments are considering legislation or regulatory actions that would require some or all parts of a drug product’s supply chain, e.g., Active Pharmaceutical Ingredients (APIs) and biotherapeutic drug...
As we sat down to write the this blog for iSPEAK to promote the 2020 ISPE Annual Meeting & Expo we wanted to look back over what has happened in the world in the first half of 2020 and to say it has been one for the history books is an understatement, it...